M

Mersana Therapeutics
D

MRSN

0.39610
USD
-0.00
(-0.75%)
مغلق
حجم التداول
11,548
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
49,366,473
أصول ذات صلة
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
N
NKTR
-0.02630
(-3.38%)
0.75210 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.